The American Association of Cancer Research Board of Directors consists of world-renowned leaders in all areas of cancer research. Manuel Hidalgo, togerther with other four individuals, have been elected to the AACR Board of Directors for the 2024-2027 term:
Manuel Hidalgo, MD, PhD, is chief of the Division of Hematology and Medical Oncology and Walter B. Wriston Professor of Pancreatic Cancer Research, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York. He is also associate director for clinical services at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and an attending physician at NewYork-Presbyterian/Weill Cornell Medical Center.
In Spain, he collaborates at Peaches Biotech, where he leads a new treatment called opT cells, born of a collaborative project with Harvard Medical School. This is a personalised therapy with Organoid Primer T Cells that activates a patient’s lymphocytes against their own tumour cells, in a completely autologous process. This research is carried out at LivingCells, Peaches’ translational oncology unit at the Hospital Universitario de Fuenlabrada (Madrid).